Abstract
Background: Patients with advanced gastric cancer who failed first line chemotherapy have a poor prognosis. However, there are few effective treatments against refractory gastric cancer. Based on encouraging results of cisplatin, 5-Fluorouracil and leucovorin (PFL) in patients with gastric cancer, nasopharyngeal cancer and other cancers, we conducted this pilot study of test PEL chemotherapy in patients with refractory advanced gastric cancer.
Method: Patients with measurable advanced gastric cancer, refractory to prior chemotherapy were eligible for study. Cisplatin 20mg/m^2/d, 5-FU 800mg/m^2/d and leucovorin 90mg/m^2/d were administered simultaneously by continuous 96-hour intravenous infusion every three weeks. Patients were evaluated for response, survival, and toxicity.
Results: Twenty patients were studied. Fifteen patients were evaluable. There were no complete response. Partial response was achieved in 4 patients. The response rate of PFL chemotherapy were 27%. The overall toxicity was tolerable. Mucositis and leukopenia were the major toxicities. No grade IV toxicities or treatment-related deaths occurred.
Conclusions: PEL chemotherpy is safe and may be effective in the treatment of refractory gastric cancer patients. Further clinical studies of PFL in gastric cancer may be indicated.
Method: Patients with measurable advanced gastric cancer, refractory to prior chemotherapy were eligible for study. Cisplatin 20mg/m^2/d, 5-FU 800mg/m^2/d and leucovorin 90mg/m^2/d were administered simultaneously by continuous 96-hour intravenous infusion every three weeks. Patients were evaluated for response, survival, and toxicity.
Results: Twenty patients were studied. Fifteen patients were evaluable. There were no complete response. Partial response was achieved in 4 patients. The response rate of PFL chemotherapy were 27%. The overall toxicity was tolerable. Mucositis and leukopenia were the major toxicities. No grade IV toxicities or treatment-related deaths occurred.
Conclusions: PEL chemotherpy is safe and may be effective in the treatment of refractory gastric cancer patients. Further clinical studies of PFL in gastric cancer may be indicated.
| Translated title of the contribution | Cisplatin，5-Fluorouracil，Leucovorin治療頑固性胃癌 |
|---|---|
| Original language | English |
| Pages (from-to) | 255-262 |
| Number of pages | 8 |
| Journal | 放射治療與腫瘤學 |
| Volume | 1 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 1994 |
| Externally published | Yes |
Keywords
- Cisplatin
- 5-Fluorouracil
- 頑固性胃癌
- leucovorin
- Fluorouracil
Fingerprint Dive into the research topics of 'Cisplain, 5-Fluorouracil (5-FU), and Leucovorin(LV) in Refractory Gastric Cancer Patients'. Together they form a unique fingerprint.
Cite this
陳榮楷, 吳秋文, 林增熙, 季匡華, 趙毅, 黃以信, 吳銘芳, 陳育民, 劉敏, 彭汪嘉康, 李壽東, & 雷永耀 (1994). Cisplain, 5-Fluorouracil (5-FU), and Leucovorin(LV) in Refractory Gastric Cancer Patients. 放射治療與腫瘤學, 1(3), 255-262. https://doi.org/10.6316/TRO/199401(3)255